In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Echocardiographic assessment of treating patients with chronic heart failure with mid-range ejection fraction by external counterpulsation

Session Poster Session 2

Speaker Tofig Jahangirov

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Treatment
  • Session type : Poster Session

Authors : R Alakbarov (Baku,AZ), T Jahangirov (Baku,AZ)

Authors:
R Alakbarov1 , T Jahangirov1 , 1Abdullaev's Research Institute of Cardiology - Baku - Azerbaijan ,

Citation:

Introduction: The new 2016 European Society of Cardiology Heart Failure (HF) Guidelines propose a new HF classification includes a new HF category with mid-range EF (HFmrEF, LVEF 40-49%). The influence of the external counterpulsation on patients with HFmrEF is unclear.
Purpose: The aim of this study was to evaluate the echocardiographic parameters of patients with HFmrEF treated with external counterpulsation (ECP).
Methods: We studied 57 patients with stable CAD undergoing one course of external counterpulsation therapy. We categorize the patients into two groups: HFmrEF (EF 40-49%) and control group (EF>50%). Echocardiographic assessment included evaluation of the chamber size and ejection fraction by 2D and Doppler measurements.
Results: The mean age of the patients was 63.07 ± 7.44 years (43 (75.4%) men and 14 (24.6%) women). The mean age of the patients included in the HFmrEF group and control group was 64.13 ± 6.86 and 62.69 ± 7.67 years (p=0.45). There were 13 men and 2 women in the HFmrEF group and 30 men and 12 women in the control group (p=0.24). All patients treated with one course of the ECP therapy (33.87 ± 5.93 and 35.02 ± 4.57 sessions, p = 0.7714). The mean EF before treatment was 44.23 ± 3.21% and 62.18 ± 6.78% (p<0.0001). After the treatment by the ECP the mean EF in both group were 52.13 ± 7.01% and 65.73 ± 6.63% respectively (p<0.0001). When comparing the dynamics of the EF and stroke volume between two groups following data obtained: for EF: +7.90 ± 7.44 and +3.55 ± 4.27% (p=0.0487); for stroke volume: +6.35 ± 13.08 and +2.51 ± 8.03 ml (p=0.0176). After the end of treatment 9 out of 15 patients in the HFmrEF group (60%) had an EF more than 50%. When comparing the dynamics of changes in the echocardiographic parameters in the HFmrEF group and the control group, non-statistically changes observed in the following parameters: end-diastolic diameter of the LV (-0.06 ± 0.18 and -0.06 ± 0.31 sm, p=0.3504), end-diastolic volume of the LV (-0.69 ± 18.43 and -0.27 ± 12.07 ml, p=0.9783), left atrial volume (-3.73 ± 16.13 and -5.19 ± 14.79 ml, p=1.0), the ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e', -0.65 ± 3.89 and -0.40 ± 2.74, p=0.9566).
Conclusion: ECP treatment was associated with an increase in EF and stroke volume in patients with HFmrEF.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are